Encorafenib + Binimetinib

Encorafenib plus binimetinib (Braftovi + Mektovi) is an approved BRAF/MEK inhibitor combination that was tested as 12 months of adjuvant therapy in stage IIB/C melanoma patients whose tumors carry BRAF V600E/K mutations, via the Pierre Fabre-sponsored COLUMBUS-AD trial (NCT05270044) [1][2]. The trial was designed to enroll ~815 patients but was terminated early after anti-PD-1 therapy (pembrolizumab, KEYNOTE-716) became the adjuvant standard-of-care in this population, making a placebo-controlled comparison ethically untenable. The primary analysis is therefore descriptive rather than a formal hazard ratio, which materially complicates any regulatory submission. The commercial stakes remain meaningful: Braftovi/Mektovi generated $197M in Q4 2025 alone (~16% YoY growth) and is trending toward $1B+ annualized revenue after the January 2025 accelerated approval in first-line BRAF V600E colorectal cancer [10].

This is not a novel compound. Encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor) are already approved together for metastatic BRAF V600-mutant melanoma (approved 2018 on the strength of the COLUMBUS pivotal trial [3]), and encorafenib plus cetuximab is approved for BRAF V600E colorectal cancer. In October 2024 the FDA approved encorafenib plus binimetinib for BRAF V600E metastatic NSCLC based on the PHAROS study [4][8]. COLUMBUS-AD was designed to extend the franchise into earlier disease: stage IIB/C melanoma, post-surgery, where no BRAF/MEK combination is yet approved as adjuvant therapy (dabrafenib plus trametinib is approved for stage III adjuvant only). The trial had no announced breakthrough or fast-track designation for this indication. Critically, COLUMBUS-AD was terminated early once anti-PD-1 adjuvant therapy (pembrolizumab per KEYNOTE-716 [9], nivolumab per CheckMate 76K) became standard-of-care for high-risk resected stage II, making the placebo arm untenable. The primary analysis is descriptive, published in European Journal of Cancer in 2026 [1]. Pierre Fabre holds ex-US commercial rights; Pfizer holds US rights following its Array BioPharma acquisition.

BRAF is a protein that normally passes growth signals from the cell surface down to the nucleus. Think of it as a relay in a chain: signal comes in, BRAF flips on, it activates the next protein (MEK), which activates the next (ERK), and the cell divides. In roughly half of melanomas, BRAF is stuck in the 'on' position because of a single mutation, most commonly V600E, and the cell keeps dividing without any external signal telling it to. Encorafenib is a small molecule that jams the mutant BRAF. Binimetinib blocks MEK, the very next step in the chain. Hitting both is not redundant, it is defensive: when you inhibit BRAF alone, cancer cells often reactivate the pathway through MEK, and skin toxicities and secondary squamous cell cancers emerge because normal cells with wild-type BRAF paradoxically get pushed into the pathway. Adding a MEK inhibitor suppresses the reactivation and reduces those skin effects. The mechanism is well-validated: three approved BRAF/MEK combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) all extend survival in metastatic BRAF V600 melanoma versus BRAF monotherapy, with encorafenib/binimetinib specifically established by the COLUMBUS pivotal trial [3].

COLUMBUS-AD (NCT05270044, also EORTC-2139) was a randomized, double-blind, placebo-controlled Phase 3 trial in patients with completely resected stage IIB or IIC melanoma harboring a BRAF V600E/K mutation [1][2]. Patients were randomized 1:1 to 12 months of encorafenib 450 mg daily plus binimetinib 45 mg twice daily, or matched placebo. The primary endpoint was recurrence-free survival (RFS), with distant metastasis-free survival and overall survival as key secondary endpoints. Planned enrollment was approximately 815 patients, powered to detect a hazard ratio of 0.55 with 97% power (91% power for HR 0.60). The comparator was placebo, which was defensible at trial design time but became indefensible during execution: no BRAF/MEK adjuvant is approved for stage II, but anti-PD-1 monotherapy became the standard for high-risk resected stage II based on KEYNOTE-716 (pembrolizumab vs placebo, RFS HR 0.62, 95% CI 0.49-0.79 at final analysis [9]) and CheckMate 76K (nivolumab). The sponsor terminated enrollment early once this shift crystallized, leaving the trial underpowered for a formal hazard ratio and forcing a descriptive analysis [1]. Any cross-trial comparison with pembrolizumab's HR 0.62 will therefore be qualitative rather than statistical.

Our model estimates a 16% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 43%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is now the dominant concern given the early termination. The trial is underpowered for a formal HR, so even a directionally positive descriptive analysis leaves regulators significant discretion. In stage IIB/C, roughly 60-75% of patients are cured by surgery alone, so an adjuvant therapy has to move a small absolute recurrence rate to be worthwhile. Safety risk is well characterized but not trivial: BRAF/MEK combinations cause pyrexia (fevers), LVEF drops (left ventricular ejection fraction - the heart's pumping efficiency, which can decline on MEK inhibitors and requires monitoring), retinal changes, and rare but serious rhabdomyolysis (breakdown of skeletal muscle that can release toxic proteins into the bloodstream and damage the kidneys). Asking asymptomatic post-surgical patients to tolerate 12 months of this is a harder sell than in metastatic disease. Regulatory risk is now front and center: FDA and EMA may accept descriptive data given the ethical rationale for early stopping, but they may equally demand a bridging study or restrict labeling. Commercial risk is the sharpest: even a clean win means competing head-to-head with pembrolizumab in a market where oncologists default to immunotherapy in melanoma. Sequencing questions also remain unresolved - specifically, whether patients who recur on adjuvant BRAF/MEK retain sensitivity to subsequent anti-PD-1 therapy - and this is a major clinical practice question that affects uptake but was not directly answered by COLUMBUS-AD.

Worth watching, with tempered expectations. Because COLUMBUS-AD was terminated early, the writeup no longer hinges on a formal hazard ratio - it hinges on how FDA and EMA interpret a descriptive analysis. A hazard ratio (the ratio of event rates between arms - a value below 1.0 favors the drug, and a HR of 0.55 would mean encorafenib/binimetinib cuts recurrence risk by 45% relative to placebo) would ideally have anchored the case, but that anchor no longer exists. Descriptive comparisons will be scrutinized against pembrolizumab's KEYNOTE-716 HR of 0.62 [9] as a benchmark. The interesting company angle is Pierre Fabre, a French privately held pharma that quietly built a real oncology business around this combination outside the US. For Pfizer, Braftovi/Mektovi generated $197M in Q4 2025 (~16% YoY growth) and is on track toward $1B+ annualized following the January 2025 first-line CRC accelerated approval [10]; an adjuvant melanoma nod would be additive but not franchise-defining. NDA/MAA filing timing is uncertain given the early termination - expect regulatory dialogue at ESMO 2026 and possibly a bridging-study requirement before any submission window opens.